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Purpose or Objective: The incidence of breast cancer is 
increasing in women over the age of 60 years. In this group of 
patients, (age associated) comorbidity is the most important 
factor influencing survival. The impact of treatment on daily 
functioning and quality of life may therefore be a more 
appropriate endpoint for therapy efficacy instead of standard 
survival outcome. Radiotherapy improves local control in 
elderly, however its impact on short-term physical and 
emotional well-being has not been well studied. This study 
describes patient reported outcomes measures (PROMs) 
during the first 6 months following radiotherapy in women 
over the age of 60 years, within a prospective breast cancer 
cohort. The effect of increasing age on PROMs was evaluated 
by comparing patients below and at least 70 years of age. 
 
Material and Methods: From October 2013 on, all breast 
cancer patients referred to the department of Radiation 
Oncology were invited to enter the UMBRELLA cohort (cohort 
for multiple breast cancer intervention studies and long-term 
evaluation). Participants consented to the collection of 
clinical data and PROMs questionnaires before and at 
predefined intervals after radiotherapy. For the purpose of 
this study, changes in quality of life (EORTC QLQ-C30 
including fatigue subscale, QLQ-BR23), anxiety and 
depression (HADS) were evaluated in patients at least 60 
years of age, between baseline and 6 months follow-up (FU). 
Changes in median levels of PROMs between baseline and 6 
months follow-up were evaluated with the paired sample t-
test. Differences between mean levels of PROMs (continuous 
scale e.g. 0-100, higher scores indicate better QoL) for the 
two age groups were evaluated with the independent sample 
t-test.  
 
Results: Between October 2013 and June 2015, a total of 848 
patients were included in the cohort, with 374 patients aged 
≥ 60 years. Preliminary analysis was performed in the first 
158 patients. At a median FU of 5.5 months after 
radiotherapy, a decline in mean overall QoL (FU score 75.0, Δ 
3.4; p=0.028), improvement of mean anxiety score (FU score 
4.6, Δ 0.8; p=0.001) and stable mean fatigue (FU score 74.9, 
Δ 0.9; p= 0.578) and depression (FU score 3.5, Δ 0.1; 
p=0.635) scores were observed. No differences between 
patients 60-69 years and from 70 years of age were observed 
for overall QoL, anxiety, depression and fatigue scores. 
Severe anxiety symptoms (HADS anxiety score > 11) were 
reported in 8.1% and 10% in age groups 60-69 and 70 years or 
older, respectively. 
 
Conclusion: In the first six months following radiotherapy, no 
clinically relevant decline in short-term emotional well-being 
and fatigue have been observed for patients at least 60 years 
of age. Overall well-being appears to be good in patients 
below and over the age of 70. Updated and more detailed 
results (e.g. effect comorbidity and toxicity) with an 
expected sample size of at least 375 patients will be 
presented in April 2016. 
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Purpose or Objective: Within a large multi-Institute 
observational study, patient reported urinary symptoms 
(PRUS) were available at baseline and at different times 
intervals after RT: aim of current analysis was to assess the 
power of the different PRUS in discriminating a severe 
impairment of urinary QoL. 
 
Material and Methods: Pts treated in 9 Institutes with radical 
3DCRT/IMRT for localized prostate cancer with conventional 
or moderate hypo-fractionation (2.35-2.7 Gy/fr) filled in 
several questionnaires, including IPSS and ICIQ. 
Questionnaires are to be filled in at baseline, at RT end, 3 
and 6 months after its conclusion, and thereafter every 6 
months up to 5 years. Current analysis focused on the IPSS 
score relative to urinary QoL (item #8, IPSS8) during the first 
two years after RT, considering a score ≥4 as a severe 
impairment. At each time interval (i.e.: baseline, RT end, 3, 
6, 12, 18, 24 months after RT) the power of the different 
PRUS, the overall IPSS, single IPSS items (IPSS1 to IPSS7) and 
ICIQ scores in discriminating patients with IPSS8≥4 was 
assessed by ROC curves: AUCs were calculated for each score 
at each timing and ROC curves compared to detect significant 
differences among scores and times.  
 
Results: The available data refer to 499, 449, 412,361, 339, 
304, 238 pts at baseline, RT end, 3,6,12,18 and 24 months 
after RT respectively. Pts with IPSS8≥4 were 50, 126, 25, 24, 
23, 28, 21 respectively. The discriminative power of the 
overall IPSS remained quite constant over time, ranging 
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between 0.84 and 0.90 without significant differences. 
Interestingly, the discriminative power of the single IPSS ites 
was different and dramatically changed over time: only IPSS6 
(straining) always showed a poor value at each time (AUC: 
0.55-0.65). All the remaining IPSS items showed not 
significantly (p>0.07) different AUCs at baseline (0.71-0.76), 
while exhibiting very different patterns after RT. IPSS2 
(frequency), IPSS4 (urgency) and IPSS7 (nocturia) showed the 
highest performances in the acute phase (AUC:0.77-0.87 at 
RT end and at 3 months). At 24 months, weak stream showed 
the highest AUC (0.87) while the remaining items ranged 
between 0.69 and 0.76. Very importantly, the AUC of ICIQ 
continuously increases from baseline/RT end (AUC=0.62-0.63) 
up to 24 months (AUC:0.82). In Figure 1a/1b the ROC curves 
at the different time intervals for overall IPSS and ICIQ are 
shown; a summary of AUC changes is shown in Figure 1c for 
all scores at baseline, end RT, 12 and 24 months. 
 
 
 
Conclusion: The analysis of a large population of 
prospectively followed patients with PRUS evaluation showed 
that the discriminative power of different symptoms in 
assessing a severely impaired urinary QoL significantly 
changes over time. As expected, the overall IPSS always 
captures a very large fraction of these patients, while the 
predictive value of ICIQ is negligible at baseline and acutely, 
becoming highly discriminative in the long term. 
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Purpose or Objective: In patients with painful bone 
metastases, radiotherapy is an effective treatment. Besides 
symptom control, quality of life (QoL) is an important 
endpoint. We focus on the course of QoL after radiotherapy. 
 
Material and Methods: In the Dutch Bone Metastasis Study, 
1,157 patients with painful bone metastases were 
randomized between one fraction of 8 Gray and six fractions 
of 4 Gray. The study proved equal effectiveness, with a pain 
response of 74%. Patients filled out weekly questionnaires for 
13 weeks and then monthly for two years or until death. 
Three QoL domain scores (physical, psychosocial and 
functional) and a visual analogue scoring of general health 
were studied. Mixed modeling was used to model the course 
of QoL and to study the influence of several characteristics. 
An effect size of ≥ 0.10/0.20 (binary or continuous variable, 
respectively) is considered a small effect and therefore 
clinically relevant. 
 
Results: In general, QoL stabilizes after a month. 
Psychosocial QoL improves temporarily after treatment. The 
level of QoL remains stable for a long time, steeply 
deteriorating at the end of life. For most QoL domains, a high 
pain score and intake of opioids are associated with worse 
QoL, with a small effect size (-0.11 to -0.27). A poor 
performance score is associated with worse functional QoL, 
with a medium effect size of 0.41. 
Figure: The modeled course of QoL after radiotherapy for 
painful bone metastases, represented in survival groups 
(patients surviving less than 3, 3-<6, 6-<12, 12-<18 and 18-
<24 months after randomization). The x-axis represents the 
months after treatment, where month 0 is the baseline 
measurement before treatment and month 1 the first months 
after treatment. The y-axis reflects the domain score of QoL, 
where the average is 0, with a standard deviation of 1. The 
higher the score, the better the QoL. 
Table: Influence of baseline and follow-up variables on QoL 
domains, with effect sizes 
 
 
 
